Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
10x Genomics Inc (TXG)
NASDAQ:TXG
Holding TXG?
Track your performance easily
TXG Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.95 - $57.90
Previous Close$15.9
Volume960.89K
Average Volume (3M)1.99M
Market Cap
$1.92B
Enterprise Value$1.61B
Total Cash (Recent Filing)$398.16M
Total Debt (Recent Filing)$85.88M
Price to Earnings (P/E)―
Beta2.09
Next Earnings
Feb 12, 2025EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding121,054,448
10 Day Avg. Volume2,124,543
30 Day Avg. Volume1,988,135
Standard Deviation0.17
R-Squared0.33
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)2.23
Price to Sales (P/S)2.61
Price to Cash Flow (P/CF)19.00
P/FCF Ratio23.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.56
Enterprise Value/Gross Profit3.94
Enterprise Value/Ebitda-12.30
Forecast
1Y Price Target
$20.40Price Target Upside28.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
10x Genomics News
PremiumCompany Announcements
10x Genomics Reports Mixed Q3 2024 Results
PremiumCompany Announcements
10x Genomics Navigates Revenue Dip with New LaunchesBulls Say, Bears Say
Bulls Say
Market LeadershipTXG's single-cell portfolio and spatial products remain number one in the market despite disruptions.
Product AdoptionThe company may return to growth mode as headwinds subside, driven by adoption of new products and improved execution.
Product LaunchThe newly launched lower-end Chromium Xo is expected to be a material revenue contributor, with initial market traction being strong.
Bears Say
Financial Performance3Q revenue of $151.7M came in significantly below expectations due to cautious customer spending and commercial restructuring initiatives.
Organizational ChallengesA major sales force overhaul has caused disruption, with 40% of US accounts having a new sales representative and 44 open commercial/sales positions.
Sales And Revenue GuidanceA $50M guidance reduction reflects ongoing challenges and no expected year-end surge.
---
Ownership Overview
2.08% Insiders
27.76% Mutual Funds
37.86% Other Institutional Investors
9.86% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TXG FAQ
What was 10x Genomics Inc’s price range in the past 12 months?
10x Genomics Inc lowest stock price was $12.95 and its highest was $57.90 in the past 12 months.
What is 10x Genomics Inc’s market cap?
Currently, no data Available
When is 10x Genomics Inc’s upcoming earnings report date?
10x Genomics Inc’s upcoming earnings report date is Feb 12, 2025 which is in 53 days.
How were 10x Genomics Inc’s earnings last quarter?
10x Genomics Inc released its earnings results on Oct 29, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.329 by $0.029.
Is 10x Genomics Inc overvalued?
According to Wall Street analysts 10x Genomics Inc’s price is currently Undervalued.
Does 10x Genomics Inc pay dividends?
10x Genomics Inc does not currently pay dividends.
What is 10x Genomics Inc’s EPS estimate?
10x Genomics Inc’s EPS estimate is -$0.29.
How many shares outstanding does 10x Genomics Inc have?
10x Genomics Inc has 106,997,610 shares outstanding.
What happened to 10x Genomics Inc’s price movement after its last earnings report?
10x Genomics Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.329. Following the earnings report the stock price went up 4.433%.
Which hedge fund is a major shareholder of 10x Genomics Inc?
Among the largest hedge funds holding 10x Genomics Inc’s share is ARK Investment Management LLC. It holds 10x Genomics Inc’s shares valued at 243M.
---
10x Genomics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.40 (28.30% Upside)
$20.40 (28.30% Upside)
Blogger Sentiment
Bearish
TXG Sentiment 67%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $171.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.0%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.29%
12-Months-Change
Fundamentals
Return on Equity
-24.87%
Trailing 12-Months
Asset Growth
-1.13%
Trailing 12-Months
Company Description
10x Genomics Inc
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company's products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.
---
TXG Company Deck
---
TXG Earnings Call
Q3 2024
0:00 / 0:00
---
TXG Revenue Breakdown
77.51% Consumables
19.96% Instruments
2.54% Services
---
TXG Stock 12 Month Forecast
Average Price Target
$20.40
▲(28.30% Upside)
Technical Analysis
Best Analysts Covering TXG
1 Year
1 Year Success Rate
8/16 ratings generated profit
1 Year Average Return
+7.09%
reiterated a buy rating 2 months ago
Copying Patrick B Donnelly's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +7.09% per trade.
---